Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$56.04
$0.54(0.97%)
At close: 4:00 PM EDT
$56.04
$0.54(0.97%)
Day’s Range― - ―
52-Week Range$25.28 - $59.30
Previous CloseN/A
Volume1.44M
Average Volume (3M)2.53M
Market Cap
$7.96B
Enterprise Value$5.56K
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)16.4
Beta0.60
Next Earnings
Nov 09, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume1,944,033
30 Day Avg. Volume2,529,227
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$64.14Price Target Upside14.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.29
Revenue Forecast (FY)$942.48M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum & Raised GuidanceSustained quarter-over-quarter sales growth and an upwardly revised full-year guidance indicate durable product adoption and scaling distribution. A >$1B annualized run-rate supports recurring revenue, operational leverage, and funding for commercialization and pipeline investment over multiple years.
High Margins And Clean Balance SheetElevated gross and net margins provide strong cash profitability potential and pricing flexibility, while minimal leverage increases strategic optionality. Together these fundamentals support reinvestment in commercial expansion and R&D, and reduce downside risk from near-term market or competitive headwinds.
Pipeline Expansion: ENHANCE & Subcutaneous ProgramA simplified initiation regimen and a potential self‑administered subcutaneous formulation materially expand addressable market and lower treatment burden. If regulatory and Phase III outcomes hold, these durable product improvements could strengthen competitive position and sustain long-term revenue growth.
Bears Say
Weak Cash ConversionPersistent negative operating and free cash flow despite strong reported earnings indicates earnings quality issues driven by working capital or non-cash items. This reduces internal funding capacity and increases reliance on cash reserves or financing to support operations and capex over the medium term.
Gross-to-net / Rebate PressureHigh gross-to-net deductions materially lower realized revenue and make top-line less predictable. Sustained mid‑60s rebate levels constrain cash recovery from sales, complicate margin modeling and weaken the durability of revenue growth absent improved contracting or payer dynamics.
Subcutaneous Pricing & Reimbursement UncertaintyUnclear pricing and reimbursement pathways for a self-administered subcutaneous formulation introduce structural adoption risk. Even with positive clinical data, weak Part D coverage or unfavorable contracting could limit market penetration and the anticipated expansion of the addressable market.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $59.30 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $7.96B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 95 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Aug 03, 2026. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.306 by -$0.256.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.37.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.05 in its last earnings report, missing expectations of $0.306. Following the earnings report the stock price went down -11.263%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.14 (14.46% Upside)
$64.14 (14.46% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 92%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 536.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.3%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 87%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
133.36%
Trailing 12-Months
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
TGTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, robust Q2 financial results, multiple positive clinical/readout milestones (ENHANCE Phase III positive; subcutaneous program advancing), growing real-world evidence, and a healthy cash position — all of which underpin upgraded guidance and an optimistic multi-year franchise opportunity. Near-term headwinds include sizable manufacturing-related charges expensed now (with potential future margin tailwinds if programs succeed), seasonality/timing risk concentrated in Q4, uncertainty around subcutaneous pricing/reimbursement, and ongoing competitive dynamics. On balance, the positive operational and clinical developments and the guidance raise materially outweigh the near-term expenses and execution risks.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$64.14
▲(14.46% Upside)
Technical Analysis
Protagonist Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Legend Biotech
―
Kymera Therapeutics
―
Ownership Overview
7.54% Insiders
18.43% Mutual Funds
2.80% Other Institutional Investors
46.42% Public Companies and
Individual Investors